Safety Profile of RhoGAM:
How to Address Patient Concerns

Common side effects of RhoGAM

Common reactions at the injection site, which can be communicated to patients as typical responses to an intramuscular injection, include¹:

• swelling
• induration
• redness
• mild pain

Other common side effects reported by patients may include¹:

• skin rash
• body aches
• slight fever

These reactions are usually mild and resolve without intervention.

Less common and rare side effects

While most RhoGAM side effects are mild, it's still important to inform patients about less common or rare adverse reactions, particularly those that may prompt them to call a healthcare provider. Serious side effects are rare but can include:

• Allergic reactions¹
  • Severe allergic (anaphylactic) reactions are rare, but possible.
  • Symptoms may include difficulty breathing, hives, or a sudden drop in blood pressure.
  • Patients should seek immediate medical attention if they experience any signs of a severe allergic reaction.
• Severe reactions¹
  • In rare cases, patients may experience more generalized symptoms beyond typical mild reactions, such as chills, dizziness, or nausea.
• Hemolytic reactions¹
  • Hemolytic reactions are very rare, but they can occur.
  • They may occur when RhoGAM is administered to Rh-positive individuals or patients who have received Rh-positive red blood cells (e.g., after an incompatible transfusion).
  • Patients should be monitored for signs and symptoms of hemolysis including fever, back pain, nausea, vomiting, hypo- or hypertension, hemoglobinuria, hemoglobinemia, elevated bilirubin and creatinine, and decreased haptoglobin.

Addressing specific patient concerns

Patients may ask about RhoGAM side effects for the mother or whether the RhoGAM shot can affect the baby.

Side effects, when they occur, are most commonly mild and limited to the injection site, such as swelling, redness, or warmth. These effects are experienced by the person receiving the injection. Serious reactions are rare.¹

It is also important to reinforce why RhoGAM is used. RhoGAM helps prevent the mother's immune system from forming antibodies against Rh-positive fetal red blood cells, which protects future pregnancies.² RhoGAM is intended for maternal administration and should not be injected into the newborn.¹

Because RhoGAM is made from human plasma, patients may ask about infection risk. There have been no documented cases of viral transmission associated with RhoGAM's manufacturing process since 1968,³ as all plasma used is rigorously tested and screened for viral material.¹

Safety considerations and patient monitoring

To ensure the safe administration of RhoGAM, consider the following:

• Patient screening¹
  • Confirm the patient's Rh-negative status before administration and ensure they have not already developed anti-D antibodies.
• Administration protocol¹
  • RhoGAM is an intramuscular injection.
  • Explain the typical timing to patients by noting that RhoGAM is generally given at 26 to 28 weeks of gestation and again after delivery if the baby is Rh-positive.
  • Additional doses may be recommended after certain procedures or significant bleeding events.
• Post-administration monitoring¹
  • Advise patients to contact their healthcare provider if they notice any unusual or severe symptoms after the injection. While most reactions are mild, monitoring helps ensure prompt management of any adverse events.